With its portfolio of cancer medicines and one of the pharma industry's most recognizable names, it's no surprise that investors are curious about whether to buy shares of Merck (NYSE: MRK).
I believe both Merck and Pfizer deserve a buy rating with an upside into 2025 and beyond. An opportunity for investors to pick up shares in these two high-quality healthcare sector leaders trading ...
Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one of them. The 10 stocks that made the cut ...
In a report released today, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...
At the start of the month, the company spent $750 million to buy an early clinical-stage treatment that aims to treat a pair of B-cell cancers from Curon Biopharmaceutical. Given Merck's extensive ...
The Motley Fool on MSN12d
Is Merck Stock a Buy?In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback